nasdaq:apls
|
821650
|
Mar 24th, 2024 12:00AM
|
Apellis Pharmaceuticals
|
64K
|
788.00
|
Open
|
|
Mar 23rd, 2024 11:53PM
|
Mar 23rd, 2024 11:53PM
|
At Apellis, we are committed to developing transformative therapies for people living with a broad range of debilitating diseases by controlling complement, part of the body’s immune system. Our work is rooted centrally at C3, which is the only target in the complement cascade that addresses all three pathways that can drive disease. Targeting C3 has broad platform potential to treat many diseases where patients have few or no treatment options available. Our programs across ophthalmology, nephrology, hematology, and neurology are further exploring what is possible by targeting C3. You can view our community guidelines here: Community guidelines: http://bit.ly/476Q8
|
Open
|
Targeted C3 Therapies, Complement System, Hematology, Ophthalmology, Nephrology, Paroxysmal Nocturnal Hemoglobinuria (PNH), Geographic Atrophy (GA), C3 Glomerulopathy (C3G), Cold Agglutinin Disease (CAD), Gene Therapy, Neurology, and Amyotrophic Lateral Sclerosis (ALS)
|
Open
|
100 Fifth Ave
|
Waltham
|
MA
|
US
|
02451
|
|
Apellis Pharmaceuticals
|
|
|
nasdaq:apls
|
821650
|
Mar 23rd, 2024 12:00AM
|
Apellis Pharmaceuticals
|
64K
|
788.00
|
Open
|
|
Mar 22nd, 2024 10:56PM
|
Mar 23rd, 2024 06:21PM
|
At Apellis, we are committed to developing transformative therapies for people living with a broad range of debilitating diseases by controlling complement, part of the body’s immune system. Our work is rooted centrally at C3, which is the only target in the complement cascade that addresses all three pathways that can drive disease. Targeting C3 has broad platform potential to treat many diseases where patients have few or no treatment options available. Our programs across ophthalmology, nephrology, hematology, and neurology are further exploring what is possible by targeting C3. You can view our community guidelines here: Community guidelines: http://bit.ly/476Q8
|
Open
|
Targeted C3 Therapies, Complement System, Hematology, Ophthalmology, Nephrology, Paroxysmal Nocturnal Hemoglobinuria (PNH), Geographic Atrophy (GA), C3 Glomerulopathy (C3G), Cold Agglutinin Disease (CAD), Gene Therapy, Neurology, and Amyotrophic Lateral Sclerosis (ALS)
|
Open
|
100 Fifth Ave
|
Waltham
|
MA
|
US
|
02451
|
|
Apellis Pharmaceuticals
|
|
|
nasdaq:apls
|
821650
|
Mar 22nd, 2024 12:00AM
|
Apellis Pharmaceuticals
|
64K
|
788.00
|
Open
|
|
Mar 21st, 2024 10:54PM
|
Mar 22nd, 2024 06:09PM
|
At Apellis, we are committed to developing transformative therapies for people living with a broad range of debilitating diseases by controlling complement, part of the body’s immune system. Our work is rooted centrally at C3, which is the only target in the complement cascade that addresses all three pathways that can drive disease. Targeting C3 has broad platform potential to treat many diseases where patients have few or no treatment options available. Our programs across ophthalmology, nephrology, hematology, and neurology are further exploring what is possible by targeting C3. You can view our community guidelines here: Community guidelines: http://bit.ly/476Q8
|
Open
|
Targeted C3 Therapies, Complement System, Hematology, Ophthalmology, Nephrology, Paroxysmal Nocturnal Hemoglobinuria (PNH), Geographic Atrophy (GA), C3 Glomerulopathy (C3G), Cold Agglutinin Disease (CAD), Gene Therapy, Neurology, and Amyotrophic Lateral Sclerosis (ALS)
|
Open
|
100 Fifth Ave
|
Waltham
|
MA
|
US
|
02451
|
|
Apellis Pharmaceuticals
|
|
|
nasdaq:apls
|
821650
|
Mar 21st, 2024 12:00AM
|
Apellis Pharmaceuticals
|
64K
|
788.00
|
Open
|
|
Mar 20th, 2024 10:53PM
|
Mar 21st, 2024 04:52PM
|
At Apellis, we are committed to developing transformative therapies for people living with a broad range of debilitating diseases by controlling complement, part of the body’s immune system. Our work is rooted centrally at C3, which is the only target in the complement cascade that addresses all three pathways that can drive disease. Targeting C3 has broad platform potential to treat many diseases where patients have few or no treatment options available. Our programs across ophthalmology, nephrology, hematology, and neurology are further exploring what is possible by targeting C3. You can view our community guidelines here: Community guidelines: http://bit.ly/476Q8
|
Open
|
Targeted C3 Therapies, Complement System, Hematology, Ophthalmology, Nephrology, Paroxysmal Nocturnal Hemoglobinuria (PNH), Geographic Atrophy (GA), C3 Glomerulopathy (C3G), Cold Agglutinin Disease (CAD), Gene Therapy, Neurology, and Amyotrophic Lateral Sclerosis (ALS)
|
Open
|
100 Fifth Ave
|
Waltham
|
MA
|
US
|
02451
|
|
Apellis Pharmaceuticals
|
|
|
nasdaq:apls
|
821650
|
Mar 20th, 2024 12:00AM
|
Apellis Pharmaceuticals
|
64K
|
789.00
|
Open
|
|
Mar 19th, 2024 11:10PM
|
Mar 20th, 2024 06:53PM
|
At Apellis, we are committed to developing transformative therapies for people living with a broad range of debilitating diseases by controlling complement, part of the body’s immune system. Our work is rooted centrally at C3, which is the only target in the complement cascade that addresses all three pathways that can drive disease. Targeting C3 has broad platform potential to treat many diseases where patients have few or no treatment options available. Our programs across ophthalmology, nephrology, hematology, and neurology are further exploring what is possible by targeting C3. You can view our community guidelines here: Community guidelines: http://bit.ly/476Q8
|
Open
|
Targeted C3 Therapies, Complement System, Hematology, Ophthalmology, Nephrology, Paroxysmal Nocturnal Hemoglobinuria (PNH), Geographic Atrophy (GA), C3 Glomerulopathy (C3G), Cold Agglutinin Disease (CAD), Gene Therapy, Neurology, and Amyotrophic Lateral Sclerosis (ALS)
|
Open
|
100 Fifth Ave
|
Waltham
|
MA
|
US
|
02451
|
|
Apellis Pharmaceuticals
|
|
|
nasdaq:apls
|
821650
|
Mar 19th, 2024 12:00AM
|
Apellis Pharmaceuticals
|
64K
|
789.00
|
Open
|
|
Mar 18th, 2024 10:49PM
|
Mar 19th, 2024 05:25PM
|
At Apellis, we are committed to developing transformative therapies for people living with a broad range of debilitating diseases by controlling complement, part of the body’s immune system. Our work is rooted centrally at C3, which is the only target in the complement cascade that addresses all three pathways that can drive disease. Targeting C3 has broad platform potential to treat many diseases where patients have few or no treatment options available. Our programs across ophthalmology, nephrology, hematology, and neurology are further exploring what is possible by targeting C3. You can view our community guidelines here: Community guidelines: http://bit.ly/476Q8
|
Open
|
Targeted C3 Therapies, Complement System, Hematology, Ophthalmology, Nephrology, Paroxysmal Nocturnal Hemoglobinuria (PNH), Geographic Atrophy (GA), C3 Glomerulopathy (C3G), Cold Agglutinin Disease (CAD), Gene Therapy, Neurology, and Amyotrophic Lateral Sclerosis (ALS)
|
Open
|
100 Fifth Ave
|
Waltham
|
MA
|
US
|
02451
|
|
Apellis Pharmaceuticals
|
|
|
nasdaq:apls
|
821650
|
Mar 18th, 2024 12:00AM
|
Apellis Pharmaceuticals
|
64K
|
789.00
|
Open
|
|
Mar 17th, 2024 11:03PM
|
Mar 18th, 2024 06:37PM
|
At Apellis, we are committed to developing transformative therapies for people living with a broad range of debilitating diseases by controlling complement, part of the body’s immune system. Our work is rooted centrally at C3, which is the only target in the complement cascade that addresses all three pathways that can drive disease. Targeting C3 has broad platform potential to treat many diseases where patients have few or no treatment options available. Our programs across ophthalmology, nephrology, hematology, and neurology are further exploring what is possible by targeting C3. You can view our community guidelines here: Community guidelines: http://bit.ly/476Q8
|
Open
|
Targeted C3 Therapies, Complement System, Hematology, Ophthalmology, Nephrology, Paroxysmal Nocturnal Hemoglobinuria (PNH), Geographic Atrophy (GA), C3 Glomerulopathy (C3G), Cold Agglutinin Disease (CAD), Gene Therapy, Neurology, and Amyotrophic Lateral Sclerosis (ALS)
|
Open
|
100 Fifth Ave
|
Waltham
|
MA
|
US
|
02451
|
|
Apellis Pharmaceuticals
|
|
|
nasdaq:apls
|
821650
|
Mar 17th, 2024 12:00AM
|
Apellis Pharmaceuticals
|
64K
|
786.00
|
Open
|
|
Mar 16th, 2024 11:46PM
|
Mar 16th, 2024 11:46PM
|
At Apellis, we are committed to developing transformative therapies for people living with a broad range of debilitating diseases by controlling complement, part of the body’s immune system. Our work is rooted centrally at C3, which is the only target in the complement cascade that addresses all three pathways that can drive disease. Targeting C3 has broad platform potential to treat many diseases where patients have few or no treatment options available. Our programs across ophthalmology, nephrology, hematology, and neurology are further exploring what is possible by targeting C3. You can view our community guidelines here: Community guidelines: http://bit.ly/476Q8
|
Open
|
Targeted C3 Therapies, Complement System, Hematology, Ophthalmology, Nephrology, Paroxysmal Nocturnal Hemoglobinuria (PNH), Geographic Atrophy (GA), C3 Glomerulopathy (C3G), Cold Agglutinin Disease (CAD), Gene Therapy, Neurology, and Amyotrophic Lateral Sclerosis (ALS)
|
Open
|
100 Fifth Ave
|
Waltham
|
MA
|
US
|
02451
|
|
Apellis Pharmaceuticals
|
|
|
nasdaq:apls
|
821650
|
Mar 16th, 2024 12:00AM
|
Apellis Pharmaceuticals
|
64K
|
782.00
|
Open
|
|
Mar 15th, 2024 10:37PM
|
Mar 16th, 2024 06:25PM
|
At Apellis, we are committed to developing transformative therapies for people living with a broad range of debilitating diseases by controlling complement, part of the body’s immune system. Our work is rooted centrally at C3, which is the only target in the complement cascade that addresses all three pathways that can drive disease. Targeting C3 has broad platform potential to treat many diseases where patients have few or no treatment options available. Our programs across ophthalmology, nephrology, hematology, and neurology are further exploring what is possible by targeting C3. You can view our community guidelines here: Community guidelines: http://bit.ly/476Q8
|
Open
|
Targeted C3 Therapies, Complement System, Hematology, Ophthalmology, Nephrology, Paroxysmal Nocturnal Hemoglobinuria (PNH), Geographic Atrophy (GA), C3 Glomerulopathy (C3G), Cold Agglutinin Disease (CAD), Gene Therapy, Neurology, and Amyotrophic Lateral Sclerosis (ALS)
|
Open
|
100 Fifth Ave
|
Waltham
|
MA
|
US
|
02451
|
|
Apellis Pharmaceuticals
|
|
|
nasdaq:apls
|
821650
|
Mar 15th, 2024 12:00AM
|
Apellis Pharmaceuticals
|
64K
|
782.00
|
Open
|
|
Mar 14th, 2024 11:39PM
|
Mar 15th, 2024 08:11AM
|
At Apellis, we are committed to developing transformative therapies for people living with a broad range of debilitating diseases by controlling complement, part of the body’s immune system. Our work is rooted centrally at C3, which is the only target in the complement cascade that addresses all three pathways that can drive disease. Targeting C3 has broad platform potential to treat many diseases where patients have few or no treatment options available. Our programs across ophthalmology, nephrology, hematology, and neurology are further exploring what is possible by targeting C3. You can view our community guidelines here: Community guidelines: http://bit.ly/476Q8
|
Open
|
Targeted C3 Therapies, Complement System, Hematology, Ophthalmology, Nephrology, Paroxysmal Nocturnal Hemoglobinuria (PNH), Geographic Atrophy (GA), C3 Glomerulopathy (C3G), Cold Agglutinin Disease (CAD), Gene Therapy, Neurology, and Amyotrophic Lateral Sclerosis (ALS)
|
Open
|
100 Fifth Ave
|
Waltham
|
MA
|
US
|
02451
|
|
Apellis Pharmaceuticals
|
|
|